Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort

Respiratory Medicine
Juan Urueta-RobledoMOX-CB Study Group

Abstract

We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized to oral therapy with either moxifloxacin 400 mg once daily for 5 days or levofloxacin 500 mg once daily for 7 days. Clinical success was achieved in 201 out of 221 (91.0%) patients in the moxifloxacin group, and in 203 out of 216 (94.0%) in the levofloxacin group, indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic eradication or presumed eradication was also similar in the two treatment groups: 92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the most common drug-related adverse event in each treatment group. The rate of discontinuation because of adverse events was very low (2%). In conclusion, a 5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day course of levofloxacin in the treatment of patients with AECB. The short treatment duration w...Continue Reading

References

Mar 22, 1995·JAMA : the Journal of the American Medical Association·S SaintD Grady
May 13, 1999·Clinical Therapeutics·M S NiedermanR Popovian
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·I A CritchleyD F Sahm

❮ Previous
Next ❯

Citations

May 3, 2014·International Journal of Antimicrobial Agents·Hartmut M Lode
Nov 5, 2013·Journal of Women's Health·Elisa Chilet-RosellMa Angeles Pardo
Apr 10, 2010·Expert Review of Anti-infective Therapy·Sanjay Sethi
May 19, 2010·Expert Review of Respiratory Medicine·Timothy E Albertson, Andrew L Chan
Oct 7, 2010·Expert Review of Respiratory Medicine·Mark H Gotfried, Ronald F Grossman
May 8, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Françoise Van Bambeke, Paul M Tulkens
May 19, 2012·Expert Opinion on Pharmacotherapy·Antoni Torres, Adamantia Liapikou
Mar 17, 2007·Respiratory Medicine·Mario CazzolaNicola A Hanania
Aug 27, 2013·The Journal of Infection·Robert WilsonMarc Miravitlles
Jun 29, 2010·Respiratory Medicine·Antonio Anzueto, Marc Miravitlles

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.